Literature DB >> 25083422

Correlations of ALDH1 expression with molecular subtypes and ABCG2 in breast cancer.

Xiaokai Bi1, Chengyi Wu1, Mingli Han1, Jianying Cai1.   

Abstract

OBJECTIVE: To investigate the correlations of aldehyde dehydrogenase 1 (ALDH1) expression with the molecular subtypes and ATP-binding cassette subfamily G member 2 (ABCG2) in breast cancer.
METHODS: The specimens from 179 cases of breast cancer were divided into five molecular subtypes according to the immunological markers (ER, PR, HER2 and CK5/6), which were luminal A, luminal B, Her2-enriched, basal-like and breast-like subtype, respectively. The expressions of ALDH1 and ABCG2 of the specimens were detected with immunohistochemical staining, and the relationship between them as well as their relations with the clinicopathological factors of breast cancer was analyzed.
RESULTS: Of the 179 cases of breast cancer, ALDH1 positive expression was present in 43 cases (24.0%). The AIDH1 expression rate showed significant difference among the different molecular subtypes of breast cancer (P=0.003). The positive expression rate of ALDH1 was 16.7% (17/102) in luminal A subtype, 21.4% (3/14) in luminal B subtype, 54.5% (13/22) in Her2-enriched subtype, 33.3% (8/24) in basal-like subtype, and 17.6% (3/17) in breast-like subtype, respectively. The positive expression of ALDH1 had no significant relation with the ABCG2 expression (P=0.052). Both ALDH1 and ABCG2 expressions were related to the administration of preoperative chemotherapy (P=0.027 and P=0.033) and ALDH1 expression was related to the HER2 expression (P=0.006).
CONCLUSIONS: With a high expression level of ALDH1, HER2 overexpression, basal-like and ABCG2-positive types were associated with poor outcomes and treatment resistance in breast cancer. The expression of ALDH1 has no obvious relation with ABCG2.

Entities:  

Keywords:  ABCG2; ALDH1; Breast cancer; molecular subtypes; neoplastic stem cells

Year:  2012        PMID: 25083422      PMCID: PMC4115713          DOI: 10.3978/j.issn.2227-684X.2012.03.04

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  24 in total

Review 1.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

2.  Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.

Authors:  Marc H G P Raaijmakers; Elke P L M de Grouw; Leonie H H Heuver; Bert A van der Reijden; Joop H Jansen; Rik J Scheper; George L Scheffer; Theo J M de Witte; Reinier A P Raymakers
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 4.  Breast-cancer stem cells-beyond semantics.

Authors:  Sunil Badve; Harikrishna Nakshatri
Journal:  Lancet Oncol       Date:  2012-01       Impact factor: 41.316

5.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

6.  Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.

Authors:  Gérald J Prud'homme; Yelena Glinka; Anna Toulina; Olga Ace; Venkateswaran Subramaniam; Serge Jothy
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

7.  Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.

Authors:  Koji Morimoto; Seung Jin Kim; Tomonori Tanei; Kenzo Shimazu; Yoshio Tanji; Tetsuya Taguchi; Yasuhiro Tamaki; Nobuyuki Terada; Shinzaburo Noguchi
Journal:  Cancer Sci       Date:  2009-03-09       Impact factor: 6.716

8.  Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.

Authors:  Tomonori Tanei; Koji Morimoto; Kenzo Shimazu; Seung Jin Kim; Yoshio Tanji; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

9.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Authors:  Christophe Ginestier; Min Hee Hur; Emmanuelle Charafe-Jauffret; Florence Monville; Julie Dutcher; Marty Brown; Jocelyne Jacquemier; Patrice Viens; Celina G Kleer; Suling Liu; Anne Schott; Dan Hayes; Daniel Birnbaum; Max S Wicha; Gabriela Dontu
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

10.  Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.

Authors:  Emina H Huang; Mark J Hynes; Tao Zhang; Christophe Ginestier; Gabriela Dontu; Henry Appelman; Jeremy Z Fields; Max S Wicha; Bruce M Boman
Journal:  Cancer Res       Date:  2009-03-31       Impact factor: 12.701

View more
  5 in total

Review 1.  Breast cancer stem cells and the challenges of eradication: a review of novel therapies.

Authors:  Fouad Saeg; Muralidharan Anbalagan
Journal:  Stem Cell Investig       Date:  2018-10-31

Review 2.  Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy.

Authors:  Prasad R Dandawate; Dharmalingam Subramaniam; Roy A Jensen; Shrikant Anant
Journal:  Semin Cancer Biol       Date:  2016-09-05       Impact factor: 15.707

3.  Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel.

Authors:  Cheng Wang; Yun-Hao Pan; Ming Shan; Ming Xu; Jia-Lin Bao; Li-Ming Zhao
Journal:  Int J Mol Sci       Date:  2015-03-02       Impact factor: 5.923

4.  Correlations of aldehyde dehydrogenase-1 (ALDH1) expression with traditional prognostic parameters and different molecular subtypes of breast carcinoma.

Authors:  Piyabi Sarkar; Keya Basu; Pubali Sarkar; Uttara Chatterjee; Madhumita Mukhopadhyay; Manoj Kumar Choudhuri; Diptendra Kumar Srakar
Journal:  Clujul Med       Date:  2018-04-25

5.  Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.

Authors:  Veena Somasundaram; Sreelatha K Hemalatha; Krishnendu Pal; Sutapa Sinha; Asha S Nair; Debabrata Mukhopadhyay; Priya Srinivas
Journal:  BMC Cancer       Date:  2016-05-26       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.